This means that 68Ga-Pentixafor could help guide therapy by identifying tumours that would respond to therapies targeting the CXCR4/CXCL12 axis; however it cannot replace 18F-FDG PET/CT in the staging of breast cancer. Here, CXCL12 is linked to neoplasm.